NRX Pharmaceuticals price to book ratio NRXP

Market value divided by the book value of the company's net assets, since 2018.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 6.1×; May 2023
9-year median: 14.6×
9-year range: 1.1× to 60.6×
Peer median: 1.6×

NRX Pharmaceuticals' price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in May 2023, at 6.1×.

On the days it had one over the last 9 years, its median was 14.6×, from 1.1× in May 2022 to 60.6× in May 2021.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	6.1×	2.7×	6.1×
2022	4.5×	1.1×	30.6×
2021	31.3×	18.8×	60.6×
2020	20.5×	5.8×	24.9×
2019	12.9×	12.7×	19.0×
2018	18.4×	17.7×	18.4×

Against its peers

Companies in Drug Manufacturers - General nearest NRX Pharmaceuticals' size, closest first, today.

Company	Price to book ratio
NRXPNRX Pharmaceuticals	n/m
LFVNLifevantage	2.2×
SPROSpero Therapeutics	1.5×
NATRNatures Sunshine Products	1.3×
ATNMActinium Pharmaceuticals	1.6×
ARVNArvinas	0.8×
PBYIPuma Biotechnology	4.1×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	2.4×
Peer median	1.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on NRX Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.